Lucid Diagnostics News

Lucid Diagnostics Partners With the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 29 08:47 ET

Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses

TipRanksApr 15 05:15 ET

Express News | Lucid Diagnostics Inc : Ascendiant Capital Markets Cuts Target Price to $8 From $8.5

Moomoo 24/7Apr 14 23:06 ET

Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path

TipRanksApr 11 16:45 ET

Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)

TipRanksApr 10 13:50 ET

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 8 08:30 ET

Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

TipRanksMar 29 07:46 ET

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 28 09:47 ET

Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position

TipRanksMar 28 07:07 ET

Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives

TipRanksMar 27 14:45 ET

Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald

Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald

Dow JonesMar 27 10:13 ET

Express News | Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3

Moomoo 24/7Mar 27 10:05 ET

Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham

Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham

Dow JonesMar 27 05:30 ET

Buy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare Reimbursement

TipRanksMar 27 05:25 ET

Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Needham analyst Mike Matson reiterates Lucid Diagnostics with a Buy and maintains $2.5 price target.

Analyst UpgradesMar 27 05:20 ET

Lucid Diagnostics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 142.72% Needham → $2.5 Reiterates Buy → Buy 11/14/2023 142.72% Needham $2.8 → $2.5 Maintains Bu

BenzingaMar 27 05:18 ET

PAVmed 4Q Loss/Shr $1.98 >PAVM

PAVmed 4Q Loss/Shr $1.98 >PAVM

Dow JonesMar 26 19:33 ET

Press Release: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 26, 2024 Lucid's quarterly revenue increased 33 percent sequentially Launched wh

Dow JonesMar 26 19:32 ET

Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q4 2023 Earnings Conference

The following is a summary of the Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript:Financial Performance:Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q

moomoo AIMar 26 16:40 ET · Conference Call

Lucid Diagnostics Reports Preliminary Q4 Results

Seeking AlphaMar 25 17:55 ET